Remember meForgot password?
    Log in with Twitter

article image'Sharpshooter' cancer drug ready for human trials, stops cancer

By Marcus Hondro     Jun 18, 2013 in Health
Cancer researchers from Toronto and Los Angeles combined research efforts and the result is a drug they call a "sharpshooter" for its ability to pinpoint enzymes and stop cancer, without harming healthy tissue. The drug is ready for human testing.
Some 100 researchers from the Family Institute for Breast Cancer Research at the Princess Margaret Cancer Centre in Toronto and the cancer research center at the University of California Los Angeles, worked on the drug, called CFI-400945. Their research has cost about $40 million, paid for by donations.
The Toronto group was lead by Dr. Tak Mak and the L.A group by Dr. Dennis Slamon and both researchers, and others from their teams, were on hand to announce the drug at a press conference in Toronto Tuesday.
Dr. Mak and Dr. Slamon met when Dr. Mak's wife was ill with breast cancer. Dr. Slamon treated her but she lost her fight with the disease in 1998 but the two researchers became friends, united by a common goal.
Dr. Mak could not hold back tears as he spoke about CFI-400945. “It’s taken a long time," he said. "And I have known many patients and I know many people who have been affected."
The researchers have applied to both the U.S. Food and Drug Administration and Health Canada to get the green light to go ahead and begin testing trials. They hope to get underway before the end of 2013.
To date, CFI-400945 has been tested on human ovarian, breast, colon, lung and pancreas cancer in mice.
More about human ovarian, breast, pancreas, lung and colon ca, CFI400945, cancer breakthrough, Cnsnews, dr tak mak
More news from Show all 12
Latest News
Top News